Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sennosides are a class of anthraquinone stimulant laxatives derived from the Senna plant (*Senna alexandrina*). They act as prodrugs that are converted by colonic bacteria into active rheinanthrones. These metabolites stimulate the myenteric plexus, leading to increased colonic motility and peristalsis, while also inhibiting water and electrolyte absorption and promoting their secretion into the intestinal lumen. In the clinical trial context of the COLONPREP study (NCT02744456) sponsored by Assistance Publique - Hôpitaux de Paris, sennosides are utilized as the mechanical bowel preparation (MBP) agent. The study evaluates the efficacy of sennosides-based MBP, alone or in combination with oral antibiotics, for the prevention of surgical site infections (SSI) in patients undergoing elective laparoscopic surgery for colon cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sennosides (Assistance publique - Hôpitaux de Paris).